Lilly Outlook For Rx: Political Pressure Will Stay, So Will Double-Digit Growth
Executive Summary
Lilly is preparing investors for a prolonged period of pressure on prices and intellectual property - with the reassurance that they can still expect double-digit annual growth from the drug industry
You may also be interested in...
Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay
Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented
Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay
Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented
Rx Pricing Debate Must Be Framed As Trade Issue, Pfizer CEO Says
The pharmaceutical industry needs to re-cast the global pricing and reimportation debate as a trade issue, Pfizer CEO Henry McKinnell told the Bear Stearns conference in New York City Sept. 8